GO:0042313 protein kinase C deactivation

Protein kinase C (PKC) is a family of serine/threonine kinases that transduce signals from diacylglycerol (DAG), calcium, and phospholipids. GO:0042313, protein kinase C deactivation, is defined as any process resulting in the inhibition or termination of PKC activity. Because PKC signaling is tightly controlled in time and space, deactivation mechanisms are as important as activation mechanisms for normal physiology. For example, in metabolic tissues, the sn-1,2-DAG-PKCε signaling axis is attenuated by DGKQ-mediated conversion of DAG to phosphatidic acid, and this deactivation step is critical for insulin sensitivity. In the retina, a photoreceptor-specific PKC is required for deactivation of the phototransduction cascade, and failure of this process causes retinal degeneration. Thus, GO:0042313 captures a conserved regulatory principle: turning PKC off is an active, regulated process with direct physiological consequences. Researchers study PKC deactivation to understand how cells avoid excessive or prolonged phosphorylation of PKC substrates. For instance, PKC-mediated phosphorylation of the complement C5a receptor on serine 334 is dynamically reversed, and this deactivation contributes to receptor desensitization. In carcinogenesis, PKC regulates p53, and deactivation of PKC signaling can influence p53-dependent responses. Atypical PKC inhibitors can synergize with 5-fluorouracil to facilitate DNA damage in colorectal cancer cells, illustrating how pharmacological deactivation of PKC has therapeutic implications. Additionally, inhibition of protein kinase D and its substrate phosphatidylinositol-4 kinase III beta blocks common human coronavirus replication, showing that deactivation of PKC-related signaling nodes can have antiviral effects. These examples highlight why GO:0042313 is a meaningful annotation for both basic and translational research. This article provides a research-grade overview of GO:0042313, including its definition, core mechanisms, key genes, disease links, and experimental methods. All statements are based on the verified literature listed in the used_citation_numbers array, and the content is optimized for both search engines and generative-AI retrieval.

GO:0042313 (protein kinase C deactivation) is a biological process term defined as any process resulting in the inhibition or termination of the activity of protein kinase C. In practice, this includes mechanisms that remove or degrade the activating lipid diacylglycerol (DAG), dephosphorylate PKC, promote PKC degradation, or otherwise block PKC catalytic activity. The synonym PKC deactivation is commonly used in the literature.

GO:0042313 is important because PKC signaling must be terminated to maintain cellular homeostasis. Without deactivation, sustained PKC activity can drive pathological outcomes such as insulin resistance, retinal degeneration, and uncontrolled cell proliferation [1,3,5]. Understanding the mechanisms of PKC deactivation provides targets for therapeutic intervention, as shown by allosteric activation of DGKQ to ameliorate obesity-induced insulin resistance and by atypical PKC inhibitors that enhance DNA damage in colorectal cancer cells.

The following genes and proteins are directly implicated in protein kinase C deactivation (GO:0042313) based on the verified literature.

PKC deactivation is regulated at multiple levels. The most direct mechanism is removal of DAG by diacylglycerol kinases such as DGKQ, which converts DAG to phosphatidic acid and thereby terminates PKCε signaling. In ischemic preconditioning, protein kinase A can act as a mediator independent of PKC, indicating that PKC deactivation may be bypassed by parallel protective pathways. In photoreceptors, a specific PKC is required for deactivation of the phototransduction cascade, and its activity is tightly linked to calcium and rhodopsin regulation. Additionally, PKC-mediated phosphorylation of the C5a receptor on serine 334 is dynamically regulated, suggesting that receptor desensitization machinery contributes to PKC deactivation. Finally, Nrf2 signaling and cell survival are influenced by PKC, implying that redox and stress pathways can modulate PKC deactivation.

The sn-1,2-DAG-PKCε signaling axis is a key driver of obesity-induced insulin resistance. DGKQ-mediated deactivation of PKCε by converting DAG to phosphatidic acid improves insulin sensitivity, and pharmacological activation of DGKQ ameliorates insulin resistance in obesity models.

In photoreceptors, a photoreceptor-specific PKC is required for deactivation of the phototransduction cascade. Loss of this deactivation leads to retinal degeneration, highlighting the importance of PKC deactivation for vision.

PKC regulates p53 during multi-stage carcinogenesis, and deactivation of PKC can influence p53-dependent tumor suppression. Atypical PKC inhibitors exhibit a synergistic effect in facilitating DNA damaging effect of 5-fluorouracil in colorectal cancer cells, suggesting that pharmacological deactivation of PKC is a potential therapeutic strategy.

Inhibition of protein kinase D and its substrate phosphatidylinositol-4 kinase III beta blocks common human coronavirus replication, indicating that deactivation of PKC-related signaling nodes can have antiviral effects.

Phosphoproteomics can quantify changes in PKC substrate phosphorylation to assess deactivation. For example, phosphorylation of the C5a receptor on serine 334 is dynamically regulated and can be monitored by mass spectrometry.

Lipidomics measures DAG and phosphatidic acid levels to determine whether DGKQ-mediated DAG removal is occurring, which is a direct readout of PKC deactivation.

Live-cell imaging with PKC biosensors can track the kinetics of PKC deactivation in real time. This is particularly useful in photoreceptors where deactivation of the phototransduction cascade is rapid.

CRISPR library screening can identify genes that regulate PKC deactivation, such as phosphatases or DGK isoforms. This approach is scalable and can be combined with phospho-specific readouts [1,6].

Researchers studying protein kinase C deactivation-related genes often need to determine whether a candidate gene is causally involved in terminating PKC signaling. EDITGENE provides CRISPR-based services to generate knockout, point-mutation, knock-in, and overexpression cell models, as well as CRISPR library screening and bioinformatics support, enabling rigorous functional studies of GO:0042313.

GO:0042313 (protein kinase C deactivation) is a critical biological process that ensures proper termination of PKC signaling. Dysregulation of this process contributes to insulin resistance, retinal degeneration, cancer, and viral replication [1,3,5,6,7]. Understanding the molecular players such as DGKQ and the C5a receptor provides opportunities for therapeutic intervention. CRISPR-based models from EDITGENE can accelerate research into this important pathway.